Back to available technologies

BCL family-mediated resistance to JAK2 inhibitors

Methods and compositions for diagnosing and treating JAK2 inhibitor resistant cancers are disclosed. In the disclosed methods, AKT and/or PBK inhibitors, ERK/MEK inhibitors, BCL-XL protein inhibitors, or combinations thereof are administered to a subject to reverse JAK2 inhibitor resistance. Accordingly, compositions containing such inhibitors may be used along with JAK2 inhibitors to successfully treat JAK2 inhibitor resistant cancers.

Duke File (IDF) Number



  • Wood, Kris
  • Winter, Peter

For more information please contact


School of Medicine (SOM)